Payload Information

General Information of This Payload

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Inhibition rate	≈10.3	%	SUN-5 cells	Gastric carcinoma	Undisclosed	[1]
Inhibition rate	≈12.2	%	HPAF-II cells	Pancreatic ductal adenocarcinoma	CVCL_0313	[1]
Inhibition rate	≈49.5	%	MDA-MB-468 cells	Breast adenocarcinoma	CVCL_0419	[1]
Inhibition rate	≈69.4	%	BT-20 cells	Invasive breast carcinoma of no special type	CVCL_0178	[1]

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

IMGC-936 [Phase 1/2]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT04622774	Phase Status	Phase 1
Clinical Description	A phase 1/2, first-in-human, open-label, dose-escalation and expansion study of IMGC936 (Anti-ADAM9 antibody drug conjugate) in patients with advanced solid tumors.
Primary Endpoint	During dose escalation measure incidence and severity of Treatment Emergent Adverse Events, During dose escalation characterize dose-limiting toxicities (DLTs), During expansion describe the overall response rate.
Other Endpoint	During dose escalation and expansion to characterize study drug concentration and the concentration of anti-drug antibody, During dose expansion describe the duration of response and progression free survival, During dose escalation to describe the objective response rate and duration of response, During dose expansion measure incidence and severity of Treatment Emergent Adverse Events. Click to Show/Hide

References

Ref 1	Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Mol Cancer Ther. 2022 Jul 5;21(7):1047-1059.
Ref 2	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors, NCT04622774